|
|||||
|
|
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive,recurrent ovarian cancer: A meta-analysis |
|
| Authors: | Chee Khoon Lee PhD Michael L Friedlander PhD Angelina Tjokrowidjaja MPH Jonathan A Ledermann MD Robert L Coleman MD Mansoor R Mirza MD Ursula A Matulonis MD Eric Pujade-Lauraine PhD Ralph Bloomfield MSc Sandra Goble MS Ping Wang PhD Rosalind M Glasspool PhD Clare L Scott PhD the Gynecologic Cancer Intergroup Meta-Analysis Committee |
| Institution: | 1. National Health and Medical Research Council Clinical Trials Center, University of Sydney, Sydney, New South Wales, Australia;2. Australia New Zealand Gynecological Oncology Group, Camperdown, New South Wales, Australia
University of New South Wales Clinical School, Prince of Wales Hospital, Sydney, New South Wales, Australia;3. National Health and Medical Research Council Clinical Trials Center, University of Sydney, Sydney, New South Wales, Australia Australia New Zealand Gynecological Oncology Group, Camperdown, New South Wales, Australia;4. University College London (UCL) Cancer Institute and UCL Hospitals, London, United Kingdom;5. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas;6. Department of Oncology, Rigshospitalet-Copenhagen University Hospital, Copenhagen, Denmark Nordic Society of Gynecological Oncology, Copenhagen, Denmark;7. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts;8. Université Paris Descartes, Assistance Publique–Hôpitaux de Paris, Paris, France Group d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO), Paris, France;9. AstraZeneca, Cambridge, United Kingdom;10. Clovis Oncology, Boulder, Colorado;11. GlaxoSmithKline, Waltham, Massachusetts;12. Beatson West of Scotland Cancer Center, National Health Service Greater Glasgow and Clyde and University of Glasgow, Glasgow, United Kingdom Scottish Gynecological Cancer Trials Group, University of Glasgow, Glasgow, United Kingdom;13. Australia New Zealand Gynecological Oncology Group, Camperdown, New South Wales, Australia Walter and Eliza Hall Institute of Medical Research, Stem Cells, and Cancer, University of Melbourne, Melbourne, Victoria, Australia |
| Abstract: | |
| Keywords: | BRCA mutation homologous recombination deficiency meta-analysis platinum-sensitive recurrent ovarian cancer poly(ADP-ribose) polymerase inhibitors |